SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)

<i>Clostridioides</i> <i>difficile</i> infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recur...

Full description

Bibliographic Details
Main Authors: Sahil Khanna, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa von Moltke, Mark H. Wilcox
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Antibiotics
Subjects:
<i>Clostridioides</i> <i>difficile</i> infection (CDI)
SER-109
microbiome therapeutics
Firmicutes
microbial diversity
recurrent CDI
Online Access:https://www.mdpi.com/2079-6382/11/9/1234

Internet

https://www.mdpi.com/2079-6382/11/9/1234

Similar Items